Ikarian Capital LLC Sells 50,000 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Ikarian Capital LLC reduced its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPRFree Report) by 47.5% during the third quarter, Holdings Channel.com reports. The fund owned 55,175 shares of the company’s stock after selling 50,000 shares during the quarter. Ikarian Capital LLC’s holdings in Jasper Therapeutics were worth $1,038,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Braidwell LP bought a new position in Jasper Therapeutics in the 3rd quarter worth about $9,091,000. Verition Fund Management LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth about $477,000. Ally Bridge Group NY LLC increased its stake in Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after acquiring an additional 180,852 shares during the last quarter. MetLife Investment Management LLC increased its stake in Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after acquiring an additional 3,873 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares in the last quarter. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Stock Up 4.7 %

Shares of NASDAQ:JSPR traded up $1.13 on Tuesday, reaching $25.10. 27,850 shares of the company traded hands, compared to its average volume of 175,084. The business’s 50-day simple moving average is $20.28 and its 200 day simple moving average is $20.92. Jasper Therapeutics, Inc. has a 52 week low of $4.00 and a 52 week high of $31.01.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Thursday, October 24th. Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research note on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Finally, Evercore ISI restated an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $74.86.

Get Our Latest Report on JSPR

About Jasper Therapeutics

(Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

See Also

Want to see what other hedge funds are holding JSPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jasper Therapeutics, Inc. (NASDAQ:JSPRFree Report).

Institutional Ownership by Quarter for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.